Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Veracyte (VCYT) stock in plain English

Free brief · no signupStart here
VCYTPublished Nov 13, 2026
Veracyte Inc
Healthcare · Diagnostics & Research
Performs genomic tests on patient biopsy samples to classify thyroid, prostate, and lung cancers.
Assets:
CLIA-certified laboratoriesOperates high-throughput clinical testing facilities in California and Texas
Decipher Prostate testFlagship genomic classifier guiding treatment decisions for localized prostate cancer
Afirma Genomic Sequencing ClassifierCore diagnostic panel that helps patients avoid unnecessary thyroid surgeries
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

87
OPS ScoreOperating finances
Latest quote
-2.07%$25.04
$2.02B
16.2×
$582.31M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 13, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was VCYT. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Veracyte (VCYT) do?

Veracyte Inc (VCYT) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Performs genomic tests on patient biopsy samples to classify thyroid, prostate, and lung cancers. Runs specialized genomic diagnostic tests that clarify cancer diagnoses from routine biopsy samples. It is worth $2.02B on the market and sold $582.31M over the last year.

Market cap
$2.02B
P/E ratio
16.2×
Annual sales
$582.31M
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 13, 2026

Brands and businesses behind VCYT

  • Afirma: Provides genomic testing on thyroid nodules to identify benign cases and earn clinical laboratory testing fees.
  • Decipher: Evaluates prostate cancer tumor biology from tissue samples to guide treatment intensity and generate test revenue.
  • Prosigna: Assesses breast cancer gene expression on surgical tissue to estimate recurrence risk and earns revenue from diagnostic kits.
  • Envisia: Helps differentiate idiopathic pulmonary fibrosis from other lung diseases through genomic sequencing of patient biopsy samples.

VCYT’s flags, in plain English

Each flag is a number from Veracyte’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.

Stupid Cash

Can pay this year's bills 5.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 3% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 71.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Profit with Caveats

Bottom-line profit of $127M in the 12 months to Sep 30, 2026, next to $99M of profit from the business. Bottom-line profit is well above what the business itself earned. The difference came from outside day-to-day operations, such as an investment gain, a tax benefit, the sale of a business or interest on its cash. Some of these may not repeat, and they make the P/E look lower than the business alone would.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about VCYT

How big is Veracyte?

Veracyte’s market cap is $2.02B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $582.31M: what customers paid the company over the last year, before any costs.

What is VCYT’s P/E ratio?

VCYT’s P/E ratio is 16.2×. Investors pay about 16.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with VCYT?

A large majority of total testing revenue depends on just two diagnostic products, Afirma and Decipher. That is one risk on Veracyte’s card. Its first risk flag is Profit with Caveats, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Veracyte’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. VCYT’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card